
==== Front
MAbs
MAbs
mAbs
1942-0862
1942-0870
Taylor & Francis

10.1080/19420862.2024.2364972
2364972
Version of Record
Correction
Correction
Correction
Correction
mAbs
7 6 2024
2024
7 6 2024
16 1 2364972Integra06 6 2024
Integra06 6 2024
Â© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
==== Body
pmcArticle title: An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy

Authors: Sarah C. Cowles, Allison Sheen, Luciano Santollani, Emi A. Lutz, Brianna M. Lax, Joseph R. Palmeri, Gordon J. Freeman, K. Dane Wittrup

Journal: mAbs

DOI: https://doi.org/10.1080/19420862.2022.2088454

It has been noted by the authors that Figure 1a was published with an error. Sequencing confirmed that the antibody CDRH1 for all the proteins produced for this work is GYTFTSHFIH, with the exception of the highest affinity mutant, as noted in Figure 1a. This corrected CDRH1 sequence is the same as the original 29F.1A12 sequence discovered in the Freeman Lab. The correction has not changed the interpretation or original conclusions of the article. The authors apologize for any inconvenience caused.NEW Figure 1:
